GS $LOXO expected approval of larotrectinib and emerging regulatory path for -292 set Loxo on a path to meaningful end market sales. However, the collaboration partnership with Bayer puts a constraint on revenue and profits and could be a potential hurdle

GS $LOXO expected approval of larotrectinib and emerging regulatory path for -292 set Loxo on a path to meaningful end market sales. However, the collaboration partnership with Bayer puts a constraint on revenue and profits and could be a potential hurdle for an acquirer.

More From BioPortfolio on "GS $LOXO expected approval of larotrectinib and emerging regulatory path for -292 set Loxo on a path to meaningful end market sales. However, the collaboration partnership with Bayer puts a constraint on revenue and profits and could be a potential hurdle"